Supplementary Material for: Retrospective Analysis of CA19-9 Decrease in Patients with Metastatic Pancreatic Carcinoma Treated with FOLFIRINOX or Gemcitabine in a Randomized Phase III Study (ACCORD11/PRODIGE4)

Marie Robert(Université Claude Bernard Lyon 1), Jaafar Bennouna(Hôpital Foch), Sophie Gourgou(Université de Montpellier), O. Bouché(Reutlingen University), Béata Juzyna(UniCancer Group), Thierry Conroy(Institut de Cancérologie de Lorraine), Marc Ychou(Université de Montpellier), Françoise Desseigne(Centre Léon Bérard), Marta Jarlier(Institut de Recherche en Cancérologie de Montpellier)
INDIGO (University of Illinois at Chicago)
January 1, 2017
10.6084/m9.figshare.5472751.v1
Cited by 0

Related Papers

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.9k
Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial
|Journal of Clinical Oncology|2011|2.1k
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
|The Lancet Oncology|2015|1.6k
Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial
|The Lancet Oncology|2021|1.3k